Advice
following an abbreviated submission:
glycopyrronium/formoterol fumarate (Bevespi Aerosphere®) is accepted for use within NHSScotland.
Indication under review: as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Glycopyrronium/formoterol fumarate (Bevespi Aerosphere®) offers an additional treatment choice in the therapeutic class of a long-acting muscarinic antagonist (LAMA) in combination with a long-acting beta2-adrenergic agonist (LABA).
Download detailed advice270KB (PDF)
Medicine details
- Medicine name:
- glycopyrronium/formoterol fumarate (Bevespi Aerosphere)
- SMC ID:
- SMC2652
- Indication:
Maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
- Pharmaceutical company
- AstraZeneca UK Ltd
- BNF chapter
- Respiratory system
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 08 April 2024